Overview

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive, unresectable malignant PM. Treatment will be administered in 21-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent or for 2 years immunotherapy maximum. Once the patient discontinues study treatment, the treatment period will end and the patient will enter the follow-up period. No cross-over is allowed between arms.

Phase:

PHASE2

Details

Lead Sponsor:

Intergroupe Francophone de Cancerologie Thoracique

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Carboplatin
cemiplimab
Cisplatin
Pemetrexed